| A | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Number | Code | Domain | Omaha System Problem | Category | Target | Brief Care Description | Care Description | Primary Care Provider | Family Nurse Practitioner | Nurse | Lab Technician | Social Work | Pharamcist | Medical Assistant | Respiratory Therapist | Pulmonologist | Allergist | Website 1 | Website 2 | Website 3 | Website 4 | Website 5 | Website 6 | |
2 | AsthMgt-1 | SNOMED_CT Problem=422979000 (PB0042); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Health-related Behaviors | Medication regimen | Case Management | medication prescription | Oral corticosteroids should be continued for 5 to 7 days after exacerbation occurs | The recommended dose of oral prednisone for adults is usually 40 to 50 mg/day. | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||||||||
3 | AsthMgt-2 | SNOMED_CT Problem=422979000 (PB0042); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Health-related Behaviors | Medication regimen | Case Management | medication prescription | Consider oral corticosteroids for patients presenting with uncontrolled asthma for 5 to 7 days | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | ||||||||||||||
4 | AsthMgt-3 | SNOMED_CT Problem=422979000 (PB0042); SNOMED_CT Cat-Tar=424490002 (GC003, TG0074) | Health-related Behaviors | Medication regimen | Case Management | medication prescription | Step down therapy when asthma symptoms have been well controlled and lung function is stable for 3 months or more. | It is recommended to step down therapy at an appropriate time such as when the patient is not traveling, not pregnant, and not experiencing current respiratory infections. It is feasible and safe to step down ICS dosing by 25-50% at 3-month intervals when symptoms are well-controlled. | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | ||||||||||||
5 | AsthMgt-4 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | Subcutaneous immunotherapy | Subcutaneous immunotherapy is recommended as an adjunct treatment to standard pharmacotherapy for individuals with mild to moderate persistent asthma with relationship of symptoms and sensitization to a specific allergen or allergens. | 1 | 1 | 1 | 1 | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines | ||||||||||
6 | AsthMgt-5 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | Prescribe asthma medications using stepwise approach | Therapy is advanced one step at a time until asthma is controlled. Reduce therapy one step at a time after asthma control is maintained for at least 3 consecutive months. | 1 | 1 | 1 | 1 | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines | |||||||||
7 | AsthMgt-6 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | Step 1: low dose combination ICS-formoterol taken as needed for relief of symptoms, and if needed before exercise | Alternative approach: low dose ICS taken whenever a SABA is taken. | 1 | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||||||||
8 | AsthMgt-7 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | Step 2: low dose ICS-formoterol, taken as needed for relief of symptoms, and if needed before exercise | Alternative therapy: daily low dose ICS plus as needed SABA. Other therapy options include: low dose ICS taken whenever SABA is used OR leukotriene receptor antagonists (LTRA) OR daily low dose ICS plus LABA | 1 | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||||||||
9 | AsthMgt-8 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | Step 3: low dose ICS-formoterol as maintenance and as needed for relief of symptoms | Alternative therapy: maintenance ICS-LABA plus as needed SABA. Other therapy options: daily medium dose ICS and SABA as needed; OR daily low dose ICS-LABA and SABA as needed; OR daily low dose ICS plus LTRA with SABA as needed; OR daily low dose ICS plus theophylline with as needed SABA. | 1 | 1 | 1 | 1 | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||||||
10 | AsthMgt-9 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | Step 4: medium-dose ICS-formoterol as maintenance and as needed for relief of symptoms | Alternative therapy: daily medium or high dose ICS-LABA with as needed SABA. Other therapy options: daily medium dose ICS plus LABA plus LAMA and SABA as needed; OR daily medium dose ICS plus LABA plus LTRA and SABA as needed; daily medium dose ICS plus LABA plus theophylline and SABA as needed. Oral corticosteroids may need to be considered during uncontrolled asthma. | 1 | 1 | 1 | 1 | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||||||
11 | AsthMgt-10 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | Step 5: referral to specialist for expert assessment, phenotyping, and add on therapy | Consider combination daily high dose ICS-LABA. Consider daily high dose ICS-LABA plus LAMA. Consider daily high dose ICS-LABA with adding on azithromycin or adding on anti-immunoglobin E, or adding on anti-interleukin-5/5R, or adding on anti-interleukin-4R alpha. Consider sputum guided treatment or bronchial thermoplasty. Consider adding on low dose oral corticosteroids with above treatments. | 1 | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||||||||
12 | AsthMgt-11 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | Consider oral corticosteroids with changes to treatment when stepping up 1 to 2 steps using the stepwise approach | 1 | 1 | 1 | 1 | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | ||||||||||||
13 | AsthMgt-12 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | If patient shows signs of severe exacerbation treatment should include initiation of SABA, controlled oxygen, systemic corticosteroids, and transfer to acute care facility | 1 | 1 | 1 | |||||||||||||||
14 | AsthMgt-13 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=424490002 (CG0003, TG0074) | Physiological | Respiration | Case Management | medication prescription | If patient shows signs of mild to moderate exacerbation start treatment with SABA, controlled oxygen if needed, and systemic corticosteroid. Reassessment should occur in one hour. | Give SABA 4 to 10 puffs by meter dose inhaler with spacer every 20 minutes for one hour. Give prednisone 40 to 50 mg for adults. Oxygen saturation target should be 93-95%. | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||||||||
15 | AsthMgt-14 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410354001 (CG003, TG0047) | Physiological | Respiration | Case Management | screening procedures | Refer to asthma specialist | It is recommended to consult an asthma specialist at step 4 of therapy or when a single life-threatening asthma exacerbation occurs, treatment goals are not met after 3-6 months, atypical or complicated presentation, initial diagnosis is severe persistent asthma, need for additional diagnostic testing, need for additional asthma self-management education, or treatment includes continuous oral corticosteroids. | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||||||
16 | AsthMgt-15 | SNOMED_CT Problem=422979000 (PB0042); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Health-related Behaviors | Medication regimen | Surveillance | screening procedures | Monitor medication adherence | 1 | 1 | 1 | 1 | 1 | 1 | https://onlinelibrary.wiley.com/doi/abs/10.1111/jan.14174 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||
17 | AsthMgt-16 | SNOMED_CT Problem=365508006 (PB0003); SNOMED_CT Cat-Tar=410392000 (CG0004, TG0027) | Environmental | Residence | Surveillance | home | Complete environmental assessment | It is recommended that all individuals with asthma of all severities should undergo an environmental assessment for exposure to allergens at home and at work, which should include either a history of symptoms on exposure or evidence of sensitization by allergy skin testing or allergen-specific immunoglobulin E. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | ||||||||
18 | AsthMgt-17 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410413008 (GC0001, TG0050) | Physiological | Respiration | Surveillance | Signs/Symptoms-Physical | Reassess asthma control/ symptoms using validated tools such as Asthma Control Test or Asthma Control Questionnaire | It is recommended to reassess asthma control with a follow-up in 2 to 6 weeks with treatment changes. Reassess patients classified with well controlled asthma every 1 to 6 months. Reassess patients classified with not well controlled asthma every 2 to 6 weeks. Reassess patients classified with poorly controlled asthma every 2 weeks. Reassessment should consist of checking medication adherence, inhaler technique, environmental factors, and comorbid conditions. | 1 | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | ||||||||
19 | AsthMgt-18 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410394004 (GC0004, TG0029) | Physiological | Respiration | Surveillance | laboratory findings | Fractional exhaled nitric oxide (FeNO) testing | In individuals 5 years and older FeNO measurement is recommended when the diagnosis of asthma is uncertain using history, clinical findings, clinical course, and spirometry, including bronchodilator responsiveness testing, or when spirometry cannot be performed. FeNO measurements are recommended as part of ongoing asthma monitoring when individuals present with persistent allergic asthma with uncertainty in choosing anti-inflammatory therapies based on history, clinical findings, and spirometry. FeNO results can be used with other clinical data to evaluate uncontrolled asthma, inhaled corticosteroid adherence, and stability for step down therapy. | 1 | 1 | 1 | 1 | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines | ||||||||||
20 | AsthMgt-19 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410392000 (CG0004, TG0027) | Physiological | Respiration | Surveillance | home | Identify asthma triggers | Examples include change in temperature, air-borne irritants, exercise, and allergans. | 1 | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | https://www.uptodate.com/contents/an-overview-of-asthma-management | ||||||||
21 | AsthMgt-20 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Physiological | Respiration | Surveillance | screening procedures | Perform peak expiratory flow rate (PEFR) | A diagnosis of asthma is considered if PEFR varies by at least 20% for 3 days per week over several weeks, or if PEFR increases by at least 20% in response to bronchodilator. It is recommended to utilize PEFR to monitor disease process, evaluate worsening symptoms, and assess response to treatments. | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | ||||||||
22 | AsthMgt-21 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Physiological | Respiration | Surveillance | screening procedures | Perform bronchial provocation test as needed | Bronchial challenge testing can be done to confirm the diagnosis of asthma. | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||||||
23 | AsthMgt-22 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Physiological | Respiration | Surveillance | screening procedures | Complete validated tests to measure and score asthma symptoms | It is recommended to complete validated tests to assess asthma control at each visit to guide management interventions. Examples include Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Therapy Assessment Questionnaire, and Asthma APGAR (Activities, Persistent, triGGers, Asthma medications, Response to therapy). | 1 | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://pubmed.ncbi.nlm.nih.gov/29531100/ | https://www.mayoclinicproceedings.org/article/S0025-6196(14)00246-8/fulltext | https://pubmed.ncbi.nlm.nih.gov/23058645/ | https://pubmed.ncbi.nlm.nih.gov/30104128/ | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||
24 | AsthMgt-23 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Physiological | Respiration | Surveillance | screening procedures | Classify asthma severity | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | ||||||||||||
25 | AsthMgt-24 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Physiological | Respiration | Surveillance | screening procedures | Classify asthma control using the components of the impairment and risk control domains | Components of the impairment domain include patient symptoms, nighttime awakenings, interference with normal activity, and use of SABA inhaler for symptom control. Components of the risk domain include number of exacerbations per year requiring oral systemic corticosteroids and treatment-related adverse effects. | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | ||||||||||||
26 | AsthMgt-25 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Physiological | Respiration | Surveillance | screening procedures | Assess asthma symptom control and future risk of adverse outcomes | It is recommended that at each opportunity asthma symptom control and future risk of adverse outcomes be assessed together. Future risk of adverse outcomes increases with high SABA use, inadequate ICS use, poor adherence to treatment plan, incorrect inhaler use, obesity, chronic sinusitis, GERD, food allergies, pregnancy, smoking, air pollution, allergen exposure, socioeconomic problems, low FEV1 less than 60% predicted, high bronchodilator reversibility, blood eosinophils, and history of one or more severe asthma exacerbations. | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | ||||||||||||
27 | AsthMgt-26 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Physiological | Respiration | Surveillance | screening procedures | Measure FEV1 at start of treatment, 3-6 months after control is achieved, and periodically for risk assessment | 1 | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||||||||
28 | AsthMgt-27 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410413008 (CG0004, TG0050) | Physiological | Respiration | Surveillance | Signs/Symptoms-Physical | Consider sending patient home after mild to moderate exacerbation | If symptoms improve without need for continued SABA, PEF improves and is 60% to 80% of personal best, oxygen saturation is 94% or greater on room air, and home resources are adequate. | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||||||||
29 | AsthMgt-28 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410410006 (CG0004, TG0047) | Physiological | Respiration | Surveillance | screening procedures | Identify risk for future exacerbations | Risk for future exacerbations independent of symptom control include history of one or more exacerbations per year, socioeconomic problems, poor adherence, incorrect inhaler technique, low forced expiratory volume in 1 second (FEV1), smoking, and blood eosinophilia. | 1 | 1 | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | ||||||||||
30 | AsthMgt-29 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=386458004 (GC0004, TG0046) | Physiological | Respiration | Surveillance | safety | Create, monitor, and manage asthma action plans | It is recommended that all patients have written asthma action plans. | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://onlinelibrary.wiley.com/doi/abs/10.1111/jan.14174 | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | https://pubmed.ncbi.nlm.nih.gov/30765356/ | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | ||||||
31 | AsthMgt-30 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410413008 (GC0004, TG0050) | Physiological | Respiration | Surveillance | signs/symptoms-physical | Allergy skin testing | Allergy skin testing is the gold standard to determine allergy sensitivities. Alternatives to allergy skin testing include in vitro testing such as ImmunoCap. | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | ||||||||||
32 | AsthMgt-31 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410413008 (GC0004, TG0050) | Physiological | Respiration | Surveillance | signs/symptoms-physical | Assess asthma symptom control by monitoring daytime or nighttime asthma symptoms, short-acting beta 2 agonist use, and limited activity | Asthma symptoms include wheezing, shortness of breath, chest tightness, and cough. It is recommended to ask the patient in the past 4 weeks have they experienced daytime asthma symptoms more than twice per week, any night awakenings due to asthma, SABA reliever use for symptoms more than twice per week, and any activity limitation from asthma? | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||||||
33 | AsthMgt-32 | SNOMED_CT Problem=129825007 (PB0041); SNOMED_CT Cat-Tar=409066002 (CG001, TG0016) | Health-related Behaviors | Health care supervision | Teaching, Guidance and Counseling | wellness | Promote lifestyle changes including quitting smoking, avoidance of second-hand smoke, increasing physical activity, and weight management | Obesity, smoking, second hand smoke exposure, and low physical activity can increase the risk for poorly controlled asthma. | 1 | 1 | 1 | 1 | 1 | https://onlinelibrary.wiley.com/doi/abs/10.1111/jan.14174 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||
34 | AsthMgt-33 | SNOMED_CT Problem=129825007 (PB0041); SNOMED_CT Cat-Tar=409066002 (CG0001, TG0016) | Health-related Behaviors | Health care supervision | Teaching, Guidance and Counseling | environment | Asthma exacerbation risk factors | It is recommended to educate all patients on asthma exacerbation risk factors such as recurrent respiratory tract infections, GERD, severe chronic sinus disease, and exposure to allergens. | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||||||
35 | AsthMgt-34 | SNOMED_CT Problem=129825007 (PB0041); SNOMED_CT Cat-Tar=424753004 (CG0001, TG0067) | Health-related Behaviors | Health care supervision | Teaching, Guidance and Counseling | dietary management | Diet high in fruits and vegetables | There is evidence suggesting that increase fruit and vegetable consumption leads to better asthma control and reduces risk of exacerbations. | 1 | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | ||||||||||||
36 | AsthMgt-35 | SNOMED_CT Problem=422979000 (PB0028); SNOMED_CT Cat-Tar=410264007 (GC0001, TG0032) | Health-related Behaviors | Medication regimen | Teaching, Guidance and Counseling | medication action/side effects | Promote medication adherence | 1 | 1 | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://onlinelibrary.wiley.com/doi/abs/10.1111/jan.14174 | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | https://www.uptodate.com/contents/an-overview-of-asthma-management | |||||
37 | AsthMgt-36 | SNOMED_CT Problem=422979000 (PB0042); SNOMED_CT Cat-Tar=409065003 (CG0001, TG0016) | Health-related Behaviors | Medication regimen | Teaching, Guidance and Counseling | medication action/side effects | Avoid medications that may make asthma worse | Aspirin and NSAIDs can cause severe exacerbations. It is important to discuss asthma and drug interactions including instructing patients to stop medications if asthma symptoms worsen. Beta blockers can cause bronchospasms. | 1 | 1 | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||||||
38 | AsthMgt-37 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410317005 (GC0001, TG0058) | Physiological | Respiration | Teaching, Guidance and Counseling | supplies | Inhaler use and technique | It is recommended to have the patient demonstrate correct inhaler technique to ensure optimal therapy. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://journals.lww.com/jaanp/Abstract/2015/08000/Practical_guidance_on_the_recognition_of.11.aspx | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | ||||||
39 | AsthMgt-38 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=409065003 (CG0001, TG0016) | Physiological | Respiration | Teaching, Guidance and Counseling | environment | Avoid indoor and outdoor air pollution | Encourage the use of non-polluting heating and cooking sources, and to vent pollutants to the outdoors whenever possible. | 1 | 1 | 1 | 1 | 1 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||||||
40 | AsthMgt-39 | SNOMED_CT Problem=106048009 (PB0028); SNOMED_CT Cat-Tar=410309002 (GC0001, TG0050) | Physiological | Respiration | Teaching, Guidance and Counseling | signs/symptoms-physical | Promote self-monitoring of asthma symptoms including worsening asthma symptoms with Asthma Action Plan | 1 | 1 | 1 | 1 | 1 | 1 | https://journals.lww.com/tnpj/Abstract/2012/11000/Update_on_asthma_management_in_primary_care.9.aspx | https://jamanetwork.com/journals/jama/article-abstract/2773482 | https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf | |||||||||
41 | |||||||||||||||||||||||||
42 | |||||||||||||||||||||||||
43 | |||||||||||||||||||||||||
44 | |||||||||||||||||||||||||
45 | |||||||||||||||||||||||||
46 | |||||||||||||||||||||||||
47 | |||||||||||||||||||||||||
48 | |||||||||||||||||||||||||
49 | |||||||||||||||||||||||||
50 | |||||||||||||||||||||||||
51 | |||||||||||||||||||||||||
52 | |||||||||||||||||||||||||
53 | |||||||||||||||||||||||||
54 | |||||||||||||||||||||||||
55 | |||||||||||||||||||||||||
56 | |||||||||||||||||||||||||
57 | |||||||||||||||||||||||||
58 | |||||||||||||||||||||||||
59 | |||||||||||||||||||||||||
60 | |||||||||||||||||||||||||
61 | |||||||||||||||||||||||||
62 | |||||||||||||||||||||||||
63 | |||||||||||||||||||||||||
64 | |||||||||||||||||||||||||
65 | |||||||||||||||||||||||||
66 | |||||||||||||||||||||||||
67 | |||||||||||||||||||||||||
68 | |||||||||||||||||||||||||
69 | |||||||||||||||||||||||||
70 | |||||||||||||||||||||||||
71 | |||||||||||||||||||||||||
72 | |||||||||||||||||||||||||
73 | |||||||||||||||||||||||||
74 | |||||||||||||||||||||||||
75 | |||||||||||||||||||||||||
76 | |||||||||||||||||||||||||
77 | |||||||||||||||||||||||||
78 | |||||||||||||||||||||||||
79 | |||||||||||||||||||||||||
80 | |||||||||||||||||||||||||
81 | |||||||||||||||||||||||||
82 | |||||||||||||||||||||||||
83 | |||||||||||||||||||||||||
84 | |||||||||||||||||||||||||
85 | |||||||||||||||||||||||||
86 | |||||||||||||||||||||||||
87 | |||||||||||||||||||||||||
88 | |||||||||||||||||||||||||
89 | |||||||||||||||||||||||||
90 | |||||||||||||||||||||||||
91 | |||||||||||||||||||||||||
92 | |||||||||||||||||||||||||
93 | |||||||||||||||||||||||||
94 | |||||||||||||||||||||||||
95 | |||||||||||||||||||||||||
96 | |||||||||||||||||||||||||
97 | |||||||||||||||||||||||||
98 | |||||||||||||||||||||||||
99 | |||||||||||||||||||||||||
100 |